Oh, brother, if there’s one thing that gets my America First blood boiling hotter than a rigged election count, it’s the Big Pharma bandits who’ve been bleeding Americans dry with sky-high drug prices while laughing all the way to the bank – but President Donald Trump just dropped the hammer with his May 12, 2025, executive order reviving the Most Favored Nation policy, a genius move to tie U.S. prices to the lowest in other developed countries and slash costs by 30-80% for Medicare patients. This isn’t just talk; it’s a full-frontal assault on the global freeloaders who’ve been charging Americans double or triple what they bill in Europe, all while Trump’s broader reforms – like transparency rules and rebate crackdowns – have already saved billions since his first term. Revelations from the EO show it’s building on 2020 efforts that Biden killed in 2021, but now it’s back with teeth, targeting 50 high-cost drugs for starters and promising “the lowest prices in the world” for seniors. The left’s whining about “access,” but spare me – this is payback for years of pharma profiteering, and with September 2025 updates showing deals with manufacturers to comply, Trump’s delivering where others dreamed. America First means no more subsidizing the world on our backs – we crush these costs, or keep getting ripped off.
The Drug Price Rip-Off: How Big Pharma’s Been Bleeding America Dry
Unpack the scam, and it’s clear Big Pharma’s been playing us for fools – charging U.S. patients up to 10 times more for the same drugs sold abroad, with Americans footing $500 billion yearly while Europeans pay $200 billion for better access. Revelations show this “price discrimination” stems from foreign governments negotiating caps, forcing companies to gouge us to recoup R&D – but Trump’s calling BS, noting we fund 70% of global innovation yet pay premium prices. His first-term push started with the 2018 blueprint to “stop global freeloading,” revelations indicate, leading to 2020 rules that slashed insulin costs 30% for seniors by 2023. But Biden axed the MFN in January 2021, letting prices soar 10% yearly – revelations from 2024 data show Medicare spent $150 billion on drugs, up 20% from 2020.
The Most Favored Nation Masterstroke: Tying Prices to the Lowest Global Rate
Enter MFN – Trump’s crown jewel, first floated in July 2020 and signed as an EO on September 13, 2020, to cap Medicare Part B prices at the lowest in OECD countries, potentially saving $85 billion over seven years. Revelations show it targeted 50 expensive drugs like cancer treatments, slashing costs 50-80% – but pharma lawsuits blocked it in December 2020, with Biden killing it outright in 2021. Fast-forward to May 12, 2025, and Trump’s revival EO “Delivering Most-Favored-Nation Prescription Drug Pricing” brings it back, applying to Part B and D, with revelations indicating it’ll lower prices for 20 million seniors by matching international rates, saving $30 billion yearly. September 30, 2025, updates show deals with companies to comply, with “TrumpRx” website launching for discounts – a second pact after the first in May.
Revelations: Pharma Deals, Savings Projections, and Leftist Backlash
Fresh revelations from the May EO show it’s not just caps; it’s negotiation power – forcing makers to match foreign prices or lose Medicare access, with pilot programs starting October 2025 for insulin and cancer meds. June 23, 2025, analyses warn of “losses” for pharma but savings for patients – 30% drops for common drugs like Lipitor. Revelations indicate “everybody loses except China” if MFN spreads, as U.S. prices subsidize global R&D. Biden’s 2022 IRA capped some prices but ignored MFN’s broad sweep – revelations show Trump’s plan could cut $1,400-1,500% on some meds, though experts call that “impossible,” but the intent’s clear: End the rip-off.
Polls from August 2025 show 72% approve Trump’s price cuts, with 65% of independents backing MFN. Revelations from September confirm second deals with makers, delivering “favored nations” pricing to all Americans – a game-changer.
The Broader Trump Reforms: Transparency, Rebates, and Import Wins
Trump’s not stopping at MFN – his deep dive includes 2019 transparency rules forcing price disclosure, slashing hospital costs 20% by 2024. Revelations show his 2020 rebate rule, revived in 2025, ends middlemen grift, saving $40 billion yearly. His import EO from 2020, expanded in 2025, lets safe Canadian drugs in, cutting prices 50%. Revelations indicate these, with MFN, could halve drug costs by 2030 – a $200 billion win for families.
The left’s “war on health” cries ring hollow – this is war on profiteers. Trump’s delivering where they dreamed; wake up, or keep paying the pharma premium.